sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its ownership in Avadel Pharmaceuticals plc, under Rule 8.3 of the Irish Takeover Panel Act. The disclosure was made on January 28, 2026. The Vanguard Group holds 6.02% interest, equating to 5,867,122 ordinary shares, in Avadel with no short positions reported.
Transactions involving US$0.01 ordinary shares included a recent purchase of 1,944 shares at 21.56 USD per share. This purchase increased Vanguard's position in Avadel, though no new stock-settled derivative agreements were disclosed.
No indemnity or dealing arrangements, such as options or derivatives commitments, were entered into. This filing ensures transparency under the Irish Takeover Regulations for stakeholders in Avadel Pharmaceuticals.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.